While working with a collection of Streptomyces strains stored in your local collection, you come across a compound that has potential broad spectrum, chemotherapeutic activity. You decide to begin working with the isolated compound at a working concentration of 55 mg/ml For a compound of this type to be considered for Phase 1 trials, it must be able to reduce bacterial abundances in vitro by at least 2 orders of magnitude. To see if your drug can accomplish this, you grow up a culture of MRSA overnight (go big!). The next day, you quantify the abundance of your overnight culture using a hemocytometer (Figure Al, dose the culture with your drug, wait 12 hours and quantify the abundance of your culture again post-antibiotic exposure (Figure B). For each instance using the hemocytometer, the cultures were diluted 3.5*103 (Figure A) and 2.7*102 (Figure B) and 0.1 mL of each dilution was added to 0.1 mL of Trypan Blue. Based on the results below, is your drug up for Phase 1 consideration? . Figure A Figure B